ABSTRACT
<p><b>OBJECTIVE</b>To study the clinical value of the preeclampsia risk assessment system, and to explore the preventive effect of Qiju Dihuang Oral Liquid (QDOL) on preeclampsia patients.</p><p><b>METHODS</b>Totally 2 000 pregnant women in the gestational week 16 -20 were equally assigned to Group A and Group B by randomized sampling. Their preeclampsia incidence was respectively assessed by preeclampsia risk assessment system and mean arterial pressure method. Of them, 200 pregnant women at predicted high risk of preeclampsia were assigned to the control group and the treatment group, 100 in each group. All received routine treatment. Patients in the treatment group additionally took QDOL, 10 mL each time, twice daily; 2 consecutive weeks per month for totally 2 weeks; lasting for six consecutive courses or ending according to the therapeutic course. The incidence was observed and compared between the two groups.</p><p><b>RESULTS</b>The predicted coincidence rate of the risk assessment system was 72.3%, higher than that of mean arterial pressure method (50.5%, P < 0.05). The incidence rate of the treatment group was 32.0%, lower than that of the control group (46.0%, P < 0.05).</p><p><b>CONCLUSIONS</b>The preeclampsia risk assessment system was more accurate. QDOL could lower the incidence of preeclampsia as intervention.</p>